# Deepbridge Capital

> Deepbridge Capital is a VC fund backing Health Care and Biotechnology. See 91 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Chester, United Kingdom
- Total investments: 91
- Last investment: Mar 2026
- Lead investor: 69%
- Fund size: $1.4M
- Last fund: Feb 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/1315949
- X (Twitter): https://www.twitter.com/deepbridgecap
- Website: http://www.deepbridgecapital.com
- Facebook: https://www.facebook.com/pages/Deepbridge-Capital-LLP/136713973775160

Deepbridge Capital is a VC fund in Chester focused on Health Care and Biotechnology. Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

## Contacts

5 contacts available for Deepbridge Capital. Shizune tracks 5 team members at Deepbridge Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/deepbridge-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $152k–$2.4M |
| Series A | $2M–$15M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 25 | 27% |
| Biotechnology | 23 | 25% |
| Medical | 18 | 20% |
| Software | 16 | 18% |
| Medical Device | 11 | 12% |

91 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 44 | 48% |
| Funding Round | 14 | 15% |
| Series A | 8 | 9% |
| Pre-Seed | 6 | 7% |
| Venture - Series Unknown | 4 | 4% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 59 | 65% |
| Spain | 1 | 1% |
| Australia | 1 | 1% |
| Singapore | 1 | 1% |
| United States | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Adrian Neilan | COO & Investment Director | 3 | https://shizune.co/investors/profile/adrian-neilan |
| Gareth Groome | Partner & Chief Financial Officer | 0 | https://shizune.co/investors/profile/gareth-groome |
| Andrew Aldridge | Partner, Head of Marketing | 0 | https://shizune.co/investors/profile/andrew-aldridge |
| Ian Warwick | Founder & Managing Partner | 8 | https://shizune.co/investors/profile/ian-warwick |
| Savvas Neophytou | Partner | 0 | https://shizune.co/investors/profile/savvas-neophytou-a7f9 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Spotlight Pathology | Spotlight Pathology develops decision support tools powered by artificial intelligence (AI) to help in the diagnosis of blood cancers. | $1.9M | Seed | Mar 11, 2026 |  |
| upLYFT | upLYFT is working on the next generation of smart wearables to help with musculoskeletal issues related to aging. Also working with pro athletes to help sporting individuals train harder and break records. | $674.9K | Seed | Jul 11, 2025 |  |
| Spotlight Pathology | Spotlight Pathology develops decision support tools powered by artificial intelligence (AI) to help in the diagnosis of blood cancers. | $570K | Seed | Apr 29, 2025 |  |
| GeneralPractice.AI | General Practice. AI is an advanced, AI-powered platform designed to transform primary care and general practice by streamlining clinical workflows, enhancing patient engagement, and reducing administrative burdens for healthcare professionals. It aims to revolutionize primary care by harnessing artificial intelligence to improve both clinical andadministrative aspects of general practice, ultimately delivering more efficient, personalized, and effective healthcare. | $327.1K | Seed | Apr 11, 2025 |  |
| HeadBox | HeadBox is a new online marketplace for creative, inspiring and offsite spaces. They are the first platform in the UK to directly link their Guests (corporate and SME bookers) to their Hosts (owners of those creative, inspiring spaces) allowing you to instantly search, book and pay in an easy and seamless way saving time and hassle when planning aSpace experience. | $3.9M | Venture - Series Unknown | Apr 03, 2025 |  |
| AI-Sight | AI-Sight is a startup that is developing an AI diabetic retinal screening system to deliver WHO-recommended diabetic eye screening services. |  | Seed | Sep 19, 2024 |  |
| Microplate Dx | Microplate Dx is a developer of diagnostic technology aimed at significantly reducing fatalities caused by drug-resistant infections.Microplate Dx, an award-winning spinout company from the University of Strathclyde in Glasgow, focuses on creating innovative diagnostic solutions to combat the significant global health challenge of antimicrobialresistance. Their technology revolves around the ingenious concept of employing highly sensitive biosensor electrodes, enhanced with miniaturized hydrogel deposits containing various antibiotics tailored to the specific infection being detected. The primary mission of Microplate DX is to proactively prevent and manage the proliferation of antimicrobial resistance on a global scale. | $3.3M | Seed | Sep 11, 2023 |  |
| Thalia Design Automation | Thalia Design Automation Ltd. operates as a semiconductor electronic design automation (EDA) company that provides software solutions to assist in the design of analog and mixed signal integrated circuits. | $2.7M |  | Jul 19, 2023 |  |
| IbisVision | Ibis Vision has developed ‘Ring of Sight’ (ROS), a unique eye test that is specifically designed for the early detection of glaucoma. Worldwide, glaucoma is the second most common cause of blindness and is caused by a build-up of pressure within the eye which in turn can damage the optic nerve and the nerve fibres from the retina. Once damage isdetected, it is usually permanent and therefore it is vital to make the diagnosis as soon as possible to commence treatment.The ROS product is based on patented technology covering the use of visual field testing using a cursor and LED screen: the product is currently configured for use within a Windows environment and has two developed tests in play; the Full Threshold Test and the Suprathreshold Test.The ROS application will be hosted remotely and deployed via the latest in Cloud technology enabling users to access the application from wherever they are situated. All data is stored on secure encrypted servers to ensure data privacy and security is maintained at all times. | $5.6M |  | May 11, 2023 |  |
| GenoMe Diagnostics | GenoMe Diagnostics develops OvaME product that helps in improvement of status quo of CA125 blood tests. | $1.7M | Seed | Mar 03, 2023 |  |

10 of 91 investments shown.

## Co-investors
- [Juno Capital Partners](https://shizune.co/investors/profile/juno-capital) — VC Fund, 3 deals together
- [LYVA Labs](https://shizune.co/investors/profile/lyva-labs) — VC Fund, 3 deals together
- [Praetura Ventures](https://shizune.co/investors/profile/praetura-capital) — VC Fund, 3 deals together
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund, 3 deals together
- [AXM Venture Capital](https://shizune.co/investors/profile/axm-venture-capital) — VC Fund, 2 deals together
- [Boundary Capital Partners LLP](https://shizune.co/investors/profile/boundary-capital) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [All VC Funds in United Kingdom](https://shizune.co/investors/vc-funds-united-kingdom)
- [All Investors in United Kingdom](https://shizune.co/investors/investors-united-kingdom)
- [Transportation VC Funds in United Kingdom](https://shizune.co/investors/transportation-vc-funds-united-kingdom)
- [Health Care Investors in United Kingdom](https://shizune.co/investors/health-care-investors-united-kingdom)
- [Health Care VC Funds in United Kingdom](https://shizune.co/investors/health-care-vc-funds-united-kingdom)
- [Health Care Investors in Europe](https://shizune.co/investors/health-care-investors-europe)

## FAQ

### What does Deepbridge Capital invest in?

Deepbridge Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Funding Round stage. Most of the 91 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Deepbridge Capital's check size?

Deepbridge Capital typically joins rounds of $152k–$2.4M at Seed and $2M–$15M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Deepbridge Capital participates in.

### How do I contact Deepbridge Capital?

Public channels for Deepbridge Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Deepbridge Capital?

The team at Deepbridge Capital includes Adrian Neilan (COO & Investment Director), Gareth Groome (Partner & Chief Financial Officer) and Andrew Aldridge (Partner, Head of Marketing). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co